Get the Stockscreener App
1.61
2.55%
0.04
After Hours:
1.62
0.01
+0.62%
Fortress Biotech Inc Stock (FBIO) Latest News
FDA extends review of Fortress Biotech's CUTX-101 drug - MSN
Is Fortress Biotech Inc (NASDAQ: FBIO) Still Hot This Week? - Stocks Register
(FBIOP) On The My Stocks Page - Stock Traders Daily
Buying Buzz: Fortress Biotech Inc [FBIO] PRESIDENT, CEO & CHAIRMAN ROSENWALD LINDSAY A MD purchases 763,359 shares of the company – Knox Daily - Knox Daily
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Mustang Bio Closes $8 Million Public Offering - citybiz
Mustang Bio Announces Closing of $8 Million Public Offering - GlobeNewswire
Mustang Bio sets terms for $8M public offering - MSN
Mustang Bio sets terms for $8M public offering By Investing.com - Investing.com Nigeria
Mustang Bio Announces Pricing of $8 Million Public Offering - The Manila Times
Mustang Bio Announces Pricing of $8 Million Public Offering - Benzinga
Capital Raise Alert: Mustang Bio Secures Fresh $8M Funding Through Strategic Share & Warrant Offering - StockTitan
Fortress Biotech (NASDAQ:FBIOP) Trading Up 0.3% – Still a Buy? - Defense World
Mustang Bio stock plunges to 52-week low of $4 - MSN
Triplex vaccine enters Phase 2 trial in stem cell donors - MSN
Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex - Yahoo Finance
Fortress Biotech Announces First Patient Dosed in Phase 2 - GlobeNewswire
Fortress Biotech (FBIO) Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination - StreetInsider.com
Fortress Biotech Launches Phase 2 Trial for Groundbreaking CMV Vaccine Triplex - StockTitan
(FBIOP) Investment Analysis - Stock Traders Daily
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Fortress Biotech, Inc. (NASDAQ:FBIO) Sees Large Increase in Short Interest - MarketBeat
Fortress Biotech (NASDAQ: FBIO) Receives Notification of Extended FDA Target Action Date for CUTX-101 - Defense World
Boom Or Bust: What Are Fortress Biotech Inc’s (NASDAQ:FBIO) Future Prospects? - Marketing Sentinel
FDA extends review of Fortress Biotech's CUTX-101 drug By Investing.com - Investing.com Canada
Reviewing LifeVantage (NASDAQ:LFVN) & Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
How the (FBIOP) price action is used to our Advantage - Stock Traders Daily
Mustang Bio announces 1-for-50 reverse stock split By Investing.com - Investing.com Canada
Mustang Bio announces 1-for-50 reverse stock split - Investing.com India
Geode Capital Management LLC Boosts Holdings in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Insiders Enjoy US$156k Return After Buying Fortress Biotech Stock - Simply Wall St
Drug to treat rare pediatric disease accepted for FDA review - The Business Journals
Fortress Biotech subsidiary's drug application accepted by FDA - Investing.com Australia
Fortress Biotech’s Subsidiary Cyprium Therapeutics Receives FDA Acceptance for CUTX-101 NDA Review - Defense World
Fortress Biotech subsidiary's drug application accepted by FDA By Investing.com - Investing.com South Africa
Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease - The Eastern Progress Online
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA - GlobeNewswire
Fortress Biotech (FBIO) and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 - StreetInsider.com
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease - Yahoo Finance
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average – What’s Next? - Defense World
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Head to Head Contrast: Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
When the Price of (FBIOP) Talks, People Listen - Stock Traders Daily
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Fortress Biotech subsidiary gains FDA approval for cSCC therapy By Investing.com - Investing.com UK
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):